CoChat

Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function

Open access
Ramin-Mangata, Stéphane, Thedrez, Aurélie, Nativel, Brice, Diotel, Nicolas, Blanchard, Valentin, Wargny, Matthieu, Aguesse, Audrey, Billon-Crossouard, Stéphanie, Vindis, Cécile, Le May, Cédric, Hulin, Philippe, Armanet, Mathieu, Gmyr, Valery, Pattou, François, Croyal, Mikaël, Meilhac, Olivier, Nobécourt, Estelle, Cariou, Bertrand, Lambert, Gilles · 2021 · Atherosclerosis
Cited by 28

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND AIMS Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) is an endogenous inhibitor of the LDL receptor (LDLR). Mendelian randomization studies suggest that PCSK9 deficiency increases diabetes risk, but the underlying mechanisms remain unknown. The aim of our study was to investigate whether PCSK9 or its inhibition may modulate beta cell function. METHODS We assessed PCSK9 and insulin colocalization in human pancreatic sections by epifluorescent and confocal microscopy. We also investigated the expression and the function of PCSK9 in the human EndoC-βH1 beta cell line, by ELISA and flow cytometry, respectively. PCSK9 was inhibited with Alirocumab or siRNA. LDLR expression and LDL uptake were assessed by flow cytometry. RESULTS PCSK9 was expressed and secreted from beta cells isolated from human pancreas as well as from EndoC-βH1 cells. PCSK9 secretion was enhanced by statin treatment. Recombinant PCSK9 decreased LDLR abundance at the surface of these cells, an effect abrogated by Alirocumab. Alirocumab as well as PCSK9 silencing increased LDLR expression at the surface of EndoC-βH1 cells. Neither exogenous PCSK9, nor Alirocumab, nor PCSK9 silencing significantly altered glucose-stimulated insulin secretion (GSIS) from these cells. High-low density lipoproteins (LDL) concentrations decreased GSIS, but the addition of PCSK9 or its inhibition did not modulate this phenomenon. CONCLUSIONS While PCSK9 regulates LDLR abundance in beta cells, inhibition of exogenous or endogenous PCSK9 does not appear to significantly impact insulin secretion. This is reassuring for the safety of PCSK9 inhibitors in terms of beta cell function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2021.03.044

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 28

Metadata

Authors
Ramin-Mangata, S., Thedrez, A., Nativel, B., Diotel, N., Blanchard, V., Wargny, M., Aguesse, A., Billon-Crossouard, S., Vindis, C., Le May, C., Hulin, P., Armanet, M., Gmyr, V., Pattou, F., Croyal, M., Meilhac, O., Nobécourt, E., Cariou, B., & Lambert, G.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2021-06
Volume
326
Pages
47-55
ISSN
0021-9150 (ISSN-L)
OpenAlex
W3153511726
Cited by
28
References
13
FWCI
5.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2021.03.044
The paper
Ramin-Mangata, S., Thedrez, A., Nativel, B., Diotel, N., Blanchard, V., Wargny, M., Aguesse, A., Billon-Crossouard, S., Vindis, C., Le May, C., Hulin, P., Armanet, M., Gmyr, V., Pattou, F., Croyal, M., Meilhac, O., Nobécourt, E., Cariou, B., & Lambert, G. (2021). Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2021.03.044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.